$XLO
Xilio Therapeutics Inc

2023 Q4 Form 10-Q Financial Statement

#000155837023018587 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.394M $6.310M
YoY Change -21.74% -11.97%
% of Gross Profit
Research & Development $11.74M $11.05M
YoY Change -21.74% -15.24%
% of Gross Profit
Depreciation & Amortization $450.0K $460.0K
YoY Change -7.98% -2.75%
% of Gross Profit
Operating Expenses $18.13M $17.36M
YoY Change -21.74% -14.08%
Operating Profit -$17.36M
YoY Change -14.08%
Interest Expense -$100.0K -$200.0K
YoY Change -66.67% 0.0%
% of Operating Profit
Other Income/Expense, Net $575.0K $613.0K
YoY Change -42.56% 47.36%
Pretax Income -$17.66M -$16.75M
YoY Change -21.41% -15.36%
Income Tax
% Of Pretax Income
Net Earnings -$17.66M -$16.75M
YoY Change -21.41% -15.37%
Net Earnings / Revenue
Basic Earnings Per Share -$0.61
Diluted Earnings Per Share -$0.64 -$0.61
COMMON SHARES
Basic Shares Outstanding 27.54M 27.54M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.70M $59.80M
YoY Change -62.87% -57.02%
Cash & Equivalents $44.70M $59.77M
Short-Term Investments
Other Short-Term Assets $3.423M $4.700M
YoY Change -16.74% 48.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $48.13M $64.48M
YoY Change -61.34% -54.69%
LONG-TERM ASSETS
Property, Plant & Equipment $5.942M $6.366M
YoY Change -18.1% -15.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $145.0K $169.0K
YoY Change -45.69% -43.85%
Total Long-Term Assets $12.80M $13.36M
YoY Change -12.75% -11.51%
TOTAL ASSETS
Total Short-Term Assets $48.13M $64.48M
Total Long-Term Assets $12.80M $13.36M
Total Assets $60.93M $77.84M
YoY Change -56.22% -50.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.050M $1.486M
YoY Change -66.4% -17.9%
Accrued Expenses $10.50M $9.404M
YoY Change 1.65% 3.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.315M $5.000M
YoY Change -50.28% 0.0%
Total Short-Term Liabilities $15.96M $16.93M
YoY Change -24.44% 0.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $8.142M $8.400M
YoY Change 17993.33% 13025.0%
Total Long-Term Liabilities $8.142M $8.400M
YoY Change 17993.33% 13025.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.96M $16.93M
Total Long-Term Liabilities $8.142M $8.400M
Total Liabilities $24.10M $25.34M
YoY Change -28.1% -18.55%
SHAREHOLDERS EQUITY
Retained Earnings -$325.5M -$307.9M
YoY Change 30.67% 35.83%
Common Stock $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.83M $52.50M
YoY Change
Total Liabilities & Shareholders Equity $60.93M $77.84M
YoY Change -56.22% -50.55%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$17.66M -$16.75M
YoY Change -21.41% -15.37%
Depreciation, Depletion And Amortization $450.0K $460.0K
YoY Change -7.98% -2.75%
Cash From Operating Activities -$13.43M -$13.37M
YoY Change -26.3% -32.84%
INVESTING ACTIVITIES
Capital Expenditures -$4.000K $0.00
YoY Change -100.79% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $4.000K $0.00
YoY Change -100.79% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.630M -2.240M
YoY Change 7661.9% 10081.82%
NET CHANGE
Cash From Operating Activities -13.43M -13.37M
Cash From Investing Activities 4.000K 0.000
Cash From Financing Activities -1.630M -2.240M
Net Change In Cash -15.06M -15.61M
YoY Change -19.71% -22.97%
FREE CASH FLOW
Cash From Operating Activities -$13.43M -$13.37M
Capital Expenditures -$4.000K $0.00
Free Cash Flow -$13.43M -$13.37M
YoY Change -28.33% -31.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001840233
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40925
dei Entity Registrant Name
EntityRegistrantName
Xilio Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1623397
dei Entity Address Address Line1
EntityAddressAddressLine1
828 Winter Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
524-2466
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
XLO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27542000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59772000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120385000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4708000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4111000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
64480000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124496000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1580000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1562000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6366000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7255000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5247000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5585000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
169000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
267000
CY2023Q3 us-gaap Assets
Assets
77842000
CY2022Q4 us-gaap Assets
Assets
139165000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1486000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3125000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9404000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10327000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1014000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
918000
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
4957000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
6667000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
68000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16929000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21119000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3165000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8415000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9189000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
45000
CY2023Q3 us-gaap Liabilities
Liabilities
25344000
CY2022Q4 us-gaap Liabilities
Liabilities
33518000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27542000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27528926
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27471607
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27425447
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
360352000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
354752000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-307857000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-249108000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
52498000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105647000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77842000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139165000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11051000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13038000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40400000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44204000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6310000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7168000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20603000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21778000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
17361000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
20206000
us-gaap Operating Expenses
OperatingExpenses
61003000
us-gaap Operating Expenses
OperatingExpenses
65982000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17361000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20206000
us-gaap Operating Income Loss
OperatingIncomeLoss
-61003000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65982000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
613000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
416000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2254000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
226000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
613000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
416000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2254000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
226000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16748000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16748000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19790000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19790000
us-gaap Net Income Loss
NetIncomeLoss
-58749000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58749000
us-gaap Net Income Loss
NetIncomeLoss
-65756000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65756000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.40
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27523821
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27523821
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27399906
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27399906
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27475579
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27475579
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27384085
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27384085
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105647000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1791000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22646000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
84792000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
140000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1800000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19355000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
67377000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1861000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16748000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
52498000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2029000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21353000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166121000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2709000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24613000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
144217000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1871000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-19790000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
126298000
us-gaap Profit Loss
ProfitLoss
-58749000
us-gaap Profit Loss
ProfitLoss
-65756000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1451000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1358000
xlo Noncash Interest Expense
NoncashInterestExpense
141000
xlo Noncash Interest Expense
NoncashInterestExpense
164000
us-gaap Share Based Compensation
ShareBasedCompensation
5452000
us-gaap Share Based Compensation
ShareBasedCompensation
6609000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
597000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1283000
xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-338000
xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-288000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1625000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-972000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-928000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
116000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-679000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-591000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55193000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
486000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1358000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-486000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1358000
us-gaap Repayments Of Debt
RepaymentsOfDebt
5000000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
64000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
64000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
140000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4916000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-48000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60595000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-58906000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121947000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199606000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61352000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140700000
us-gaap Interest Paid Net
InterestPaidNet
474000
us-gaap Interest Paid Net
InterestPaidNet
380000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
371000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59772000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139143000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1580000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1557000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61352000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140700000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-307900000
us-gaap Net Income Loss
NetIncomeLoss
-58700000
us-gaap Net Income Loss
NetIncomeLoss
-65800000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59800000
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12079000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11673000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5713000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4418000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6366000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7255000
us-gaap Depreciation
Depreciation
1400000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Concentrations of Credit Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company holds all cash and cash equivalents at accredited financial institutions. Bank accounts in the United States are generally insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. Substantially all of the Company’s cash and cash equivalents are FDIC insured, including funds held through an insured cash sweep program. The Company has not experienced any losses in its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:3pt;visibility:hidden;">​</span></p>
us-gaap Depreciation
Depreciation
1300000
CY2023Q3 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
4553000
CY2022Q4 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
3178000
CY2023Q3 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
4051000
CY2022Q4 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
5413000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
627000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1536000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
200000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9404000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10327000
CY2019Q3 xlo Lessee Operating Lease Area Leased
LesseeOperatingLeaseAreaLeased
27830
CY2019Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2019Q3 xlo Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
P5Y
CY2023Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1600000
CY2022Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1600000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10231375
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8653472
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1861000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1871000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5452000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6609000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4960553
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.04
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
89000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3738555
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.75
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2757
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
872873
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.77
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7823478
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M14D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2768685
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M28D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.88
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7899671
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5066345

Files In Submission

Name View Source Status
0001558370-23-018587-index-headers.html Edgar Link pending
0001558370-23-018587-index.html Edgar Link pending
0001558370-23-018587.txt Edgar Link pending
0001558370-23-018587-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xlo-20230930.xsd Edgar Link pending
xlo-20230930x10q.htm Edgar Link pending
xlo-20230930xex10d3.htm Edgar Link pending
xlo-20230930xex31d1.htm Edgar Link pending
xlo-20230930xex31d2.htm Edgar Link pending
xlo-20230930xex32d1.htm Edgar Link pending
xlo-20230930_def.xml Edgar Link unprocessable
xlo-20230930_lab.xml Edgar Link unprocessable
xlo-20230930_pre.xml Edgar Link unprocessable
xlo-20230930x10q_htm.xml Edgar Link completed
xlo-20230930_cal.xml Edgar Link unprocessable